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Abstract
Nature has provided the developing immune system with several
checkpoints important for the maintenance of tolerance and the
prevention of autoimmunity. The regulatory mechanisms operating
in the periphery of the system are mediated by subsets of regu-
latory cells, now considered principal contributors to peripheral
tolerance. Regulatory T cells (Tregs) have received titanic interest
in the past decade, placing them at the centre of immuno-
suppressive reactions. However, it has become clearer that other
immune suppressive cells inhibit auto-reactivity as effectively as
Tregs. The function of Tregs and other regulatory cells in rheuma-
toid arthritis will be discussed in this review.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disorder
characterized by chronic systemic and synovial tissue
inflammation that, if not therapeutically tackled, ultimately
leads to bone and cartilage destruction. Like other auto-
immune diseases, RA results from a cascade of reactions,
beginning with the breakdown of tolerance and leading to
dysregulated chronic inflammation in one or multiple organs
[1]. During synovial inflammation, critical events include neo-
angiogenesis, cellular hyperplasia, and a massive influx of
inflammatory cells such as T cells, B cells,fibroblast-like syno-
viocytes, macrophages, and dendritic cells (DCs). Cellular
infiltration, and subsequent cellular proliferation, is largely
orchestrated by a complex interplay of pro-inflammatory
cytokines,chemokines, and matrix metalloproteinases [1,2]. In
addition to expressing a variety of pro-inflammatory cytokines,
the joint hosts immunosuppressive cells producing anti-
inflammatory cytokines (that is, IL-10 and transforming growth
factor (TGF)β) [3]. The balance between the various
regulatory CD4+ T cell subsets, collectively termed regulatory
T cells (Tregs), IL-10-producing regulatory B cells (Bregs),
regulatory DCs and suppressive macrophages on the one
hand, and pro-inflammatory effector lymphocytes and
monocyte-derived cells on the other, is likely to dictate the
choice between tolerance and autoimmunity. In this review
we have collated data from models that demonstrate the
existence of different regulatory cells to generate a more
unified view of how immunoregulatory cells may cooperate in
the choice between maintenance and breakdown of
tolerance in chronic inflammation.
Regulatory cells: is there only one
immunoregulatory queen? Regulatory T cells
Regulatory CD4+ T cells can be divided into two main subsets,
natural Tregs (nTregs) and induced Tregs (iTregs), which
develop in the thymus and the periphery, respectively. nTregs
express the transcription factor forkhead box protein 3 (FoxP3)
during development in the thymus [4]. FoxP3 plays a key role in
a sophisticated developmental program that nudges the
immature T cell lineage into a regulatory pathway during
positive selection on high affinity T cell receptor ligands [4]. Via
the T cell receptor, activated Tregs can exert non-antigen
specific bystander suppression of other T cells [5]. Tregs have
been shown to require cell-to-cell contact to suppress target
cells in vitro [6]. Binding of CTLA-4 on Tregs to CD80 and
CD86 on effector T cells (Teffs), infusion of cyclic AMP
through gap junctions or direct cytolic mechanisms have been
reported to be involved in Treg-mediated suppression [7]. In
addition, Treg expression of glucocorticoid-induced tumour
necrosis factor receptor (GITR) and Neuropillin-1 facilitate cell
contact-mediated suppression of non-T cells such as
endothelial cells and antigen-presenting cells (GITR) or DCs
(Neuropillin-1) [8,9]. Efficient regulatory function requires an
initial burst, followed by consumption, of endogenous IL-2
followed by the release of other soluble factors such as IL-10
and/or TGFβ and IL-35 [10-13].
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Unlike FoxP3+ nTregs, which are fully functional upon thymic
exit, iTregs are generated from naïve CD4+ T cells in the
periphery, where they acquire suppressive capacity [14].
iTRegs can acquire the expression of FoxP3 (FoxP3+ iTregs)
in response to antigens presented on non-inflammatory
antigen-presenting cells coupled to TGFβ and IL-2. FoxP3+
iTregs also require Foxp3 for their suppressive activity and
phenotypic stability [7,14]. Data from several studies support
the notion that iTregs are as important as nTregs in peripheral
tolerance. In mice, FoxP3+ iTregs effectively control experi-
mental autoimmune encephalomyelitis (EAE), colitis and type 1
diabetes [15-17]. Early thymectomised mice display impaired
nTreg development but normal Foxp3+ iTreg numbers, and
these mice develop a less severe disease than Foxp3-
deficient mice, suggesting that, early in life, iTreg cells may be
vital due to the delay in nTreg development [18]. In addition,
the foetal peripheral adaptive immune system generates
FoxP3+ iTregs, in response to cross placenta maternal cells,
that inhibit anti-maternal immunity. These iTregs persist at
least into early adulthood [19]. iTregs are also important in
adult life as they have been identified in situ and positively
correlate with a clinical improvement of allergy symptoms
[20]. Nonetheless, it remains difficult to dissect the relative
contributions of iTregs and nTregs in the maintenance of
tolerance, since once in the periphery they are phenotypically
undistinguishable.
FoxP3- iTregs can be identified based on their specific
cytokine profile, producing only IL-10 and/or TGFβ [21,22].
FoxP3- iTregs display a low proliferative capacity and inhibit
the development of both Th1-mediated experimental
autoimmune diseases and Th2-mediated allergy [21,23].
They are induced in vitro and in vivo by sustained stimulation
with IL-10, immature DCs or a combination of vitamin D3 and
dexamethasone [24,25]. FoxP3- iTregs also include TGFβ-
producing Th3 cells and CD4+CD25- latency-associated
peptide (LAP)+ T cells, which are central in mediating oral
tolerance [26]. Th3 regulatory cells depend on IL-2 for
survival and exert suppression primarily via TGFβ, but also via
IL-10 [27,28]. LAP+CD4+CD25- T cells are important in the
inhibition of diabetes and colitis, and suppression is TGFβ-
dependent but IL-10-independent [21,29].
Other lymphocytes, including CD8+FoxP3+ cells,  γδ and
invariant natural killer T cells are immunosuppressive [30-32],
but since their functions in RA remain largely elusive they
have not been included in this review.
Regulatory cells in human rheumatoid
arthritis and in experimental arthritis
The first clues that Tregs are critical in mediating protection
from arthritis were provided by the observations that
depletion of CD4+CD25+ cells in a collagen-induced arthritis
(CIA) model, which closely mimics RA, resulted in increased
severity and incidence of CIA [33] and that adoptive transfer
of CD4+CD25+ cells in the early stages of disease slowed
CIA progression [34]. The transferred Tregs migrated to the
arthritic joint where they acted locally to reduce inflammation
[34]. However, it could not be definitively concluded that
exacerbation of the disease seen following depletion of
CD4+CD25+ cells was exclusively due to Treg depletion, as it
may also be a result of the depletion of other regulatory
CD25+-expressing cells, such as CD8+ T cells, Tr1, or Bregs
[35]. Several other studies, using a variety of experimental
models for arthritis, have now confirmed the importance of
Tregs in ‘dampening’ arthritogenic responses [36-38] and
their relevance in the maintenance of a ‘stable’ non-immuno-
genic environment.
Translation of data from experimental models to patients with
RA has proved to be challenging. Our laboratory originally
reported that Tregs are dysfunctional in RA as they cannot
suppress tumour necrosis factor (TNF)α and interferon
(IFN)γ released by responder CD4+ T cells [39]. We and
others have also described that therapies that target TNFα,
such as infliximab, increase the percentage of Tregs in
circulation, and that Tregs isolated from patients responding
to anti-TNFα therapy reacquire suppressive capacity
[39,40]. Valencia and colleagues [40] elegantly demon-
strated that TNFα directly suppresses human Tregs via
signalling through TNF receptor II and inhibition of FoxP3
transcription. van Amelsfort and colleagues [41] have also
shown that Tregs cultured with pro-inflammatory cytokines
lose their capacity to inhibit responder T cell proliferation
and cytokine production. However, paradoxically, TNFα is a
potent immuno-modulator of CD4+ T cells and can, in some
cases, prevent experimental autoimmune diseases such as
type I diabetes and lupus [42,43]. In addition, TNF receptor
II is chiefly expressed on both human and murine Tregs and
is associated with higher suppressive capacity [44,45]. The
dual functions of TNFα suggest that the mechanisms driving
the induction of Tregs after TNFα blockade have not been
completely elucidated.
Equally, the data relating to Treg number and function in RA
are a complex jigsaw that remains to be assembled. In
contrast to the lack of inhibition exerted by Tregs identified as
CD4+CD25high and isolated from peripheral blood, other
studies have shown that CD4+CD25+ Tregs isolated from
joints of patients with active arthritis had a more powerful
suppressor activity than peripheral CD4+CD25+ Tregs [46].
There is a disparity between the number of Tregs found in the
peripheral blood of RA patients compared to the numbers of
Tregs isolated from the joint of the same individuals, with
more Tregs in the inflamed joints than in circulation,
suggesting that compensatory mechanisms take place at the
site of inflammation [46,47]. The discordance between
different studies could be due to different methods of Treg
purification (inclusion of all CD25 [46] versus the inclusion of
only CD4+CD25high T cells [39]) and/or a difference between
the choices of the patients enrolled in each study. Whereas
in our study only patients who failed all the conventionaltreatments and, hence, had more active RA were assessed,
RA patients with a broader range of clinical scores were
included in the van Amelsfort study [39,41]. These results
suggest that the overall degree of inflammation, the balance
between pro- and anti-inflammatory cells and the amount of
cytokines they produce might influence Treg suppressive
capacity.
CD4+ T cells producing IL-17 (Th17) play a pivotal role in
the induction of arthritic diseases and should also be
included in this complex ‘balancing equation’ [48,49].
Aberrant Th17 responses have been found in several
experimental autoimmune models, including CIA [50] and
EAE [51]. Patients with juvenile idiopathic arthritis displayed
an increased number of IL-17+ cells in both their synovial
fluid and peripheral blood compared to the numbers in the
peripheral blood of healthy volunteers [52]. It has been
recently reported that disease severity in juvenile idiopathic
arthritis is positively correlated with the numbers of Th17
cells and inversely correlated with Treg number, although
not with their function, suggesting that the balance of Th17
cells and Tregs may be critical for disease outcome [52]. At
the moment it remains to be formally proven whether
functionally active Tregs can limit Th17 expansion or
whether an uncontrolled Th17 expansion observed in
patients with RA is responsible for the lack of Treg
suppression.
The first evidence for the existence of IL-10-producing CD4+
T cells in inflamed synovia was provided in 1994 by Feldman
and collaborators [53], who showed that IL-10 was spon-
taneously produced in most synovial tissues isolated from RA
patients. The major producers of IL-10 were T cells in the
mononuclear cell aggregates and monocytes in the lining
layer. The authors also showed that neutralization of endo-
genously produced IL-10 in the RA synovial membrane
cultures resulted in increased levels of the pro-inflammatory
cytokines TNFα and IL-1β, thus demonstrating the active anti-
inflammatory role of IL-10.
The discovery of new and more specific markers has allowed
better discrimination of the various Treg subsets in vivo.
Comprehensive studies comparing different Treg subsets
should be carried out in the same cohorts of patients to give
an overview of how the inflammatory environment influences
all Treg responses in patients with RA. Fundamentally, a more
‘holistic’ approach should be considered for shaping future
therapies as it is likely that the effect of anti-inflammatory
cytokines released by Tregs, such as IL-10 and TGFβ, is
antagonised by the myriad pro-inflammatory factors present in
the synovia. Perfusion of Tregs is unlikely to provide a long
standing clinical benefit to patients with active autoimmune
disease unless the pro-inflammatory environment is recon-
ditioned to a ‘neutral state’, where Tregs can effectively
maintain tolerance rather than re-condition existing inflam-
mation (Figure 1).
Are other immune regulatory cells the
‘vassals’ of regulation?
Regulatory B cells
Traditionally, B cells have been seen as antibody secreting
‘machines’, but recently their capacity to produce distinct
arrays of cytokines during chronic inflammation has been
explored. Several groups have described B cells with regu-
latory function (Bregs) that can restrain immune responses
and prevent autoimmune diseases, including arthritis [35,54].
Bregs were originally identified by Charles Janeway, who
showed that B cell-deficient mice immunized with myelin
basic protein in complete Freund’s adjuvant were unable to
recover from EAE [55]. These original data were confirmed
and extended by Fillatreau and colleagues [56], who revealed
that resolution of disease depends upon the presence of
IL-10-producing B cells. Further, we have demonstrated that
in vitro activation of arthritogenic B cells with an agonistic
anti-CD40 induces the differentiation of IL-10-producing B
cells. When adoptively transferred, these activated B cells
can control CIA development via the suppression of the
autoreactive Th1 response [57]. These results were consis-
tent with the inhibition of the spontaneous Th1 response of
Palmerston North mice with lupus-like disease after the
adoptive transfer of CpG-activated IL-10-producing B cells
[58]. In addition, it has been reported that treatment of
DBA/1 mice with apoptotic cells at the time of immunization
with collagen type II (CII) suppresses Th1 differentiation and
antibody production, and protected mice from arthritis via the
induction of IL-10+ Bregs [59].
Unlike the Treg field, there is a lack of overall consensus
about the combinations of markers that identify Bregs. We
recently demonstrated that the IL-10+ B cells in the CIA
model are confined within the immature transitional 2-
marginal zone precursor (T2-MZP) B cell subset and are
CD19+, CD21high, CD23high, CD24high and CD1dhigh [60].
Adoptive transfer of T2-MZP B cells from naïve or
convalescent mice prevented the recipient syngenic DBA/1
mice from developing arthritis. Although the mechanism of
action of these T2-MZP Bregs has not been completely
elucidated, we demonstrated that the protection is IL-10-
mediated, since T2-MZP B cells isolated from IL-10 knockout
mice failed to protect against the Th1-driven autoimmune
response in recipient mice. Analysis of T cells isolated from
T2-MZP B cell-treated mice revealed a reduction in prolifera-
tion following in vitro CII stimulation, confirming that Bregs
can reduce autoreactive T cell responses [60]. Unlike other
autoimmune models, depletion of Tregs using anti-CD25
antibodies did not alter the capacity of Bregs to suppress
arthritis, suggesting that Bregs, at least in CIA, are not
dependent on natural Tregs for their suppressive effects.
We have also identified B regs with similar phenotype
(T2-MZP) in the MRL/lpr mice lupus-like disease model, and
demonstrated that they can be enriched upon short term in
vitro culture with agonistic anti-CD40 [61]. Transfer of anti-
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mice significantly improved renal disease and survival by an
IL-10-dependent mechanism. In this model, T2-like Bregs not
only suppressed Th1 responses, but induced the
differentiation of FoxP3-IL-10+CD4+ T cells, which could
regulate other CD4+ T cells. Interestingly, the therapeutic
effect of Breg transfer could be recapitulated by
administration of agonistic anti-CD40 [61]. Although the
therapeutic use of agonistic anti-CD40 monoclonal
antibodies is not a viable therapy for autoimmune diseases,
enrichment of Bregs in vitro followed by their transfer might
represent a feasible alternative for autoimmune patients who
have failed other biological therapies.
Marginal zone B cells have been also proposed as
candidates for Bregs in experimental models of rheumatic
diseases due to their capacity to up-regulate IL-10 in
response to CpG [62] or after exposure to apoptotic cells
[59]. However, it remains to be formally proven whether their
IL-10 production is paralleled by functional suppressive
capacity. B-1 cells are also known to release IL-10 and IgM
natural autoantibody and they have been proposed to play a
protective role in individuals predisposed to autoimmunity and
in patients with atherosclerosis via enhancing the clearance
of apoptotic cells [63-65].
Despite increased interest in Breg biology, the existence of
an equivalent population in humans has not yet been fully
proven. Populations of IL-10-producing B cells have been
identified in healthy individuals as well as in patients with
multiple sclerosis [66]. However, their phenotype,
suppressive functions and whether they can be exploited for
immune therapy of autoimmune disease are the subject of
current investigations.
Regulatory dendritic cells
DCs are mainly regarded as specialized professional antigen
presenting cells. In a resting environment, in the absence of
any inflammation or pathogenic elements, most DCs are at an
immature stage of development, characterized by a high
endocytic capacity and low surface expression of major
histocompatibility (MHC) and co-stimulatory molecules. In the
presence of microbial infections or inflammation, DCs rapidly
mature and become activated [67]. The outcome of DC-T cell
interactions is regulated by several factors, including the state
of DC maturation and/or the presence of cytokines. Immature,
or semi-matured DCs with low expression of CD40 and
MHCII can tolerize T cells and prevent unwanted immune
reactions. In the CIA model, stimulation of DCs with TNFα
generates DCs with a strong suppressive capacity. Transfer
of these TNFα-induced DCs suppressed arthritis in recipient
syngeneic mice [68]. It is clear that the micro-environmental
stimuli that condition DCs are important and numerous
strategies based on immunosuppressive agents, such as
vitamin-D3, IL-10, TGFβ, glucocorticoids, detaxomethasone,
and N-acetyl-l-cysteine, have been used to induce tolerogenic
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Figure 1
The balance between pro- and anti-inflammatory cell types and cytokines dictates arthritic disease development. (a) During inflammation the joint is
overwhelmed by an influx of pro-inflammatory cell types. This activates the immune cells such as macrophages already present in the joint and
results in a massive increase in pro-inflammatory cytokines, including IL-17, IL-1β, IFNγ and tumour necrosis factor (TNF)α. Even though regulatory
cells can be identified in arthritic joints, it is likely that the pro-inflammatory environment is over-powering and so renders these cells unable to
suppress. This results in the joint architecture being destroyed and the synovia becoming inflamed. (b) Regulatory cell types that secrete anti-
inflammatory cytokines, including IL-10 and transforming growth factor (TGF)β, are in control of the resolution of joint inflammation in a non-
autoimmune individual. This prevents the activation of the Th1 response, antibody production, effector B cell commitment and macrophage
activation and so precludes damage to the joint architecture. Breg, regulatory B cell; DC, dendritic cell; IFN, interferon; IL, interleukin; iTreg,
induced Treg; nTreg, natural Treg; Treg, regulatory T cell.DCs [69,70]. Amongst them, induction of regulatory DCs via
stimulation with vasoactive intestinal peptide (VIP) holds
therapeutic promise. Gonzalez-Rey and Delgado have shown
that exposure of immature DCs to VIP induces the
differentiation of tolerogenic DCs, which efficiently controlled
the development of arthritis in an adoptive transfer system
[71]. It is possible that maturing DCs exposed in vivo to VIP
might differentiate into regulatory DCs that help to keep the
regulatory pool ‘topped up’.
Regulatory DCs also appear to be the mediators of oral
tolerance, a process that refers to the immunological hypo-
responsiveness initiated by ingestion of protein antigens [72].
Since oral tolerance is initiated in the gut-associated
lymphoid tissue, DCs in the Peyer’s Patches are believed to
be responsible for priming CD4+ T cells that secrete IL-10
and IL-4 or TGFβ in response to oral tolerance regimes; thus,
DCs appear to be inducing iTreg (Tr1 or Th3) differentiation
[73]. Repeated oral administration of CII to susceptible
strains induces tolerance and prevents the induction of CIA,
which has been ascribed to a specific subset of DCs that are
CD11c+ and CD11b+ [74]. The transfer of CII-pulsed
regulatory DCs prevented arthritis development and
promoted the differentiation of IL-10 and/or TGFβ-producing
Tregs (Th3) [74-76] Unfortunately, despite positive results in
both experimental arthritis and phase II trials, no effect was
observed in phase III trials of CII in RA [77]. The possibility of
harnessing DCs for the generation of both induced Tregs and
adaptive Tr1 cells represents one of the major goals in
immunotherapy at the moment as it could potentially replace
non-specific immunosuppressive drugs.
Suppressor macrophages
Macrophages are present at sites of inflammation and have
previously been shown to play a pivotal role in the induction
and perpetuation of RA [78]. Recently emigrated monocytes
mature into macrophages in the RA synovial membrane.
Subsets of monocytes differentially colonize the synovial
sublining and lining layer as well as the superficial and deep
layers of the lining. A possible functional diversity of mono-
cytes in these areas, which is emphasized by the expression
of different activation markers and adhesion molecules, is
believed to contribute to disease progression [79].
Like many other immune cells, the role of macrophages
cannot be simply associated with inflammation, and a distinct
subset of macrophages can also act as suppressive cells via
immunomodulatory factors, including IL-10, reactive oxygen
species (ROS), and tryptophan and arginine catabolism
[80-82]. Macrophages can be divided into specific subsets
according to functional and phenotypical criteria. ‘Classically’
activated macrophages are monocytes stimulated with IFNγ,
alone or in combination with IL-12 and IL-23, which differen-
tiate into M1-polarised cells that induce the differentiation of
Th1 type responses. Conversely, monocytes activated in the
presence of IL-4 and IL-13 differentiate into M2-polarized
cells producing IL-10, which favours a Th2 type response
[83]. Although not yet extended to arthritis, it is interesting to
note that monocytes differentiating in the presence of Tregs
acquire a suppressive phenotype and function [84]. Mono-
cytes entering tissues can undergo phenotypic switches
between M1 and M2 macrophage phenotypes due to soluble
micro-environmental factors (cytokines, chemokines, growth
factors, and tissue cells), and the balance of activated Teffs
and Tregs affects their maturation [85]. In addition, macro-
phages differentiating upon stimulation with macrophage
colony-stimulating factor express indoleamine 2,3-dioygenase
and inhibit T cell proliferation in vitro by depleting the
important amino acid tryptophan from co-cultures in response
to T cell activation [86]. The adoptive transfer of in vitro
TGFβ-generated antigen presenting F4/80+ peritoneal
macrophages induced the differentiation of TGFβ-producing
Tregs in primed and naïve mice. Interestingly, whereas in
naïve mice the majority of induced Tregs were CD4+ and
produced TGFβ, in primed mice the induced Tregs were
CD8+ Tregs and the response involved Fas-mediated
deletion of Teffs [87]. Macrophages derived from myeloid
suppressor cells from tumour-bearing mice and cancer
patients could suppress T cell proliferation in vitro and induce
the differentiation of FoxP3+ Tregs in vivo using IL-10/IFNγ-
dependent mechanisms [88]. In humans, monocyte-derived
macrophages can convert CD4+ naïve T cells, but not
activated T cells, into Tregs, suggesting that macrophages
might curb immune responses during tolerogenic conditions
but not during inflammation [89].
In the context of arthritis, it has been shown that macro-
phages control disease development via ROS. Mice with a
mutation in the neutrophil cytosolic factor 1 (Ncf1) gene
develop exacerbated arthritis, an enhanced IgG response and
delayed-type hypersensitivity responses against CII [90].
Further work by the same group demonstrated that resis-
tance to the disease relies upon the ROS produced by
macrophages. Transgenic mice over-expressing functional
Ncf1 in macrophages develop a significantly milder disease
compared to wild-type mice and suppress T cell responses
during antigen presentation [91]. Interestingly, whilst a signifi-
cant reduction of IL-2 and proliferation was observed, the
levels of IFNγ remained unchanged despite the reduced
severity of the disease. Unequivocally, these studies challenge
the common dogma that antioxidants are anti-inflammatory
and provide an additional class of drugs with strong potential
as therapeutics [92].
Conclusion
Our findings and those from others challenge the paradigm of
Tregs as the sole co-ordinating cell type directly involved in
the regulation of autoimmunity. Further study is needed to
understand the interaction between different immunoregu-
latory cells and unravel the outcomes of these interactions. A
more cohesive approach aimed at the expansion of multiple
regulatory cells could be the key to designing better therapies
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this review suggests that therapies aimed at drastically
depleting or entirely eliminating T or B cells from patients with
autoimmunity need to be carefully re-evaluated, since the
depletion of regulatory subsets could have long-lasting
deleterious effects.
Outstanding questions
It is well documented that deletion of FoxP3+ cells either in
adult or neonatal mice can cause catastrophic autoimmunity
[93] and FoxP3 mutations in humans cause lethal diseases
[94,95]. Recent data have shown that the ablation of all DCs,
although not only those with regulatory functions, leads to
development of autoimmunity, which was, however, much
milder than the aggressive rapidly fatal disease that occurs
when Foxp3+ Tregs are deleted [96]. However, although it
remains to be revealed whether the selective deletion of
regulatory B cells, DCs or macrophages also leads to the
development of severe forms of autoimmunity, until then
regulatory T cells should be placed at the top of the putative
‘regulatory pyramid’.
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